Active — Not RecruitingPhase 2

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

United States250 participantsStarted 2015-01

Plain-language summary

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. more than 14 days or more than 5 half-lives prior to study entry, whichever is shorter.
✓. more than 14 days for radiotherapy.

What they're measuring

Objective overall response rate (ORR) as per local investigator's assessment

Timeframe: 36 months

Duration of response per RECIST v1.1 as per local Investigator's assessment.

Timeframe: 36 Months

Trial details

NCT IDNCT02912949

SponsorPartner Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Solid Tumours Harboring NRG1 Fusion trials